secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001193125-25-004527
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir announces 1-for-23 reverse stock split effective Jan 15, 2025
---------------------------------------------------------------------

- Board approved 1-for-23 reverse stock split; effective 4:05 PM ET Jan 15, 2025.
- Stock to trade on split-adjusted basis on Nasdaq from Jan 16, 2025; CUSIP 019818202.
- No fractional shares; cash payment in lieu at closing price on Jan 15.
- Reverse split authorized by stockholders at special meeting on Jan 9, 2025 in connection with proposed merger with Kalaris Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525004527/0001193125-25-004527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525004527/d834173d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-004527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer